Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Pediatric Blood & Cancer|October 16, 2019
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemiaEmily R Finch, Colton A Smith, Wenjian Yang, et al.
Cancers|January 11, 2024
The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid LeukemiaValeria Ceolin, Sae Ishimaru, Seth E Karol, et al.
Haematologica|April 23, 2026
Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapyRebecca K Voss, Wenqing Qi, La'Ron Browne, et al.
The Lancet. Haematology|July 8, 2026
Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion studyKatelyn P Daniels, Stanley B Pounds, Huiyun Wu, et al.
Clinical Pharmacology and Therapeutics|March 26, 2021
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase HypersensitivityYiwei Liu, Wenjian Yang, Colton A Smith, et al.
Blood|November 22, 2015
Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemiaSeth E Karol, Leonard A Mattano, Wenjian Yang, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease RelapseMasayuki Umeda, Pandurang Kolekar, Anna Lw Huskey, et al.
Bio-Protocol|August 14, 2023
Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia CellsLauren Rowland, Brandon Smart, Anthony Brown, et al.
Haematologica|July 1, 2021
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapySeth E Karol, Deqing Pei, Colton A Smith, et al.
Clinical Pharmacology and Therapeutics|September 20, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyMichael T Eadon, David W Hein, Michael A Andersen, et al.
Pageof 9